Previously unidentified targets like CASP9, MAPK9, and MCL1 were unveiled, supported by existing NSCLC literature, enhancing the pivotal role of empirical validation in network pharmacology. This evidence concerns the gene MAPK9 and non-small cell lung carcinoma.